We consider Cel Sci somewhat reliable.
Cel Sci secures Sharpe Ratio (or Efficiency) of 0.0225, which signifies that the company had 0.0225% of return per unit of risk over the last month. Our standpoint towards foreseeing the volatility of a stock is to use all available market data together with stock specific
technical indicators that cannot be
diversified away. We have found twenty-one
technical indicators for Cel Sci, which you can use to evaluate future volatility of the firm. Please confirm Cel Sci Risk Adjusted Performance of 0.0391,
downside deviation of 4.24, and Mean Deviation of 3.68 to double-check if the risk estimate we provide is consistent with the expected return of 0.11%.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include CEL SCI income statement, its balance sheet, and the statement of cash flows. Potential CEL SCI investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although CEL SCI investors may use each financial statement separately, they are all related. The changes in CEL SCI's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CEL SCI's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of CEL SCI
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of CEL SCI performance into the future periods or doing a reasonable stock valuation. The intrinsic value of CEL SCI shares is the value that is considered the true value of the share. If
the intrinsic value of CEL is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares CEL SCI. Please read more on our
fundamental analysis page.
Watch out for price decline
Please consider monitoring CEL SCI on a daily basis if you are holding a position in it. CEL SCI is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as CEL SCI stock to be traded above the $1 level to remain listed. If CEL SCI stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How effective is CEL SCI in utilizing its assets?
CEL SCI Corp reports assets on its Balance Sheet. It represents the amount of CEL resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, CEL SCI aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect CEL volatility, please check the breakdown of all its
fundamentals.
Are CEL SCI Earnings Expected to grow?
The
future earnings power of CEL SCI involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of CEL SCI factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. CEL SCI
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of CEL
expected earnings.
CEL SCI Gross Profit
CEL SCI Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing CEL SCI previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show CEL SCI Gross Profit growth over the last 10 years. Please check CEL SCI's
gross profit and other
fundamental indicators for more details.
Another angle On CEL SCI
The modest gains experienced by current holders of Cel Sci could raise concerns from stakeholders as the firm it trading at a share price of
12.74 on very low momentum in volume. The company executives have been quite successful in maneuvering the stock at opportune times to take advantage of all market conditions in
November. The stock standard deviation of daily returns for 30 days investing horizon is currently 4.74. This high volatility is attributed to the latest market swings and not so good earnings reports for some of the Cel Sci partners.
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Cel Sci has an asset utilization ratio of 5.23 percent. This denotes that the company is making $0.0523 for each dollar of assets. An increasing asset utilization means that Cel Sci is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets8.8 M | Assets Non Current18.7 M | |
| Current Assets | 8.82 Million | 31.7 |
| Assets Non Current | 18.72 Million | 67.29 |
| Goodwill | 279,688 | 1.01 |
Cel Sci has a fair chance to close above $12.99 mark in January
Cel Sci new semi deviation upsurges over 4.09. Cel Sci exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Cel Sci individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Cel Sci future systematic risk.
Our Takeaway on Cel Sci Investment
While some firms in the biotechnology industry are either recovering or due for a correction, Cel Sci may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current Cel Sci valuation and our trade advice on Cel Sci is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Cel Sci.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of CEL SCI Corp. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com